TIMOLOL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Timolol, and when can generic versions of Timolol launch?
Timolol is a drug marketed by Epic Pharma Llc, Alembic, Dr Reddys, Eugia Pharma, Gland Pharma Ltd, Sandoz, Akorn, Amring Pharms, Apotex, Apotex Inc, Bausch And Lomb, Fdc Ltd, Fougera, Hikma, Ingenus Pharms Llc, Mankind Pharma, Micro Labs, Pacific Pharma, Sentiss Pharma, Ani Pharms, Chartwell Rx, Mylan, Quantum Pharmics, Rising, Teva, Usl Pharma, and Watson Labs. and is included in fifty NDAs.
The generic ingredient in TIMOLOL is timolol maleate. There are fifteen drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the timolol maleate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Timolol
A generic version of TIMOLOL was approved as timolol maleate by MYLAN on June 8th, 1990.
Summary for TIMOLOL
US Patents: | 0 |
Applicants: | 27 |
NDAs: | 50 |
Raw Ingredient (Bulk) Api Vendors: | 33 |
Clinical Trials: | 238 |
Patent Applications: | 7,750 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for TIMOLOL |
Drug Sales Revenues: | Drug sales revenues for TIMOLOL |
DailyMed Link: | TIMOLOL at DailyMed |
Recent Clinical Trials for TIMOLOL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Laboratorios Poen | Phase 4 |
The University of Texas Health Science Center, Houston | Phase 4 |
Taipei Medical University WanFang Hospital | N/A |